Table II.
Ratio of the area under the concentration-time curve (AUC) of voriconazole N-oxide (NO) to voriconazole (VRC) in plasma (Left) and interstitial space fluid (Right) of four healthy volunteers with different CYP2C19 genotype-predicted phenotypes in dependence of the respective dosing interval
| CYP2C19 metabolizer | AUCNO/AUCVRC | |||||
|---|---|---|---|---|---|---|
| Plasma | Interstitial space fluids | |||||
| Dosing interval | Dosing interval | |||||
| 1 | 5 | 7 | 1 | 5 | 7 | |
| Rapid metabolizer | 3.30 | 4.57 | 4.71 | 1.84 | 1.75 | 2.49 |
| Normal metabolizer | 2.71 | 2.34 | 2.78 | 1.54 | 1.67 | 2.28 |
| Rapid/poor metabolizer | 1.26 | 1.04 | 1.13 | 0.608 | 0.604 | 0.852 |
| Intermediate metabolizer | 1.11 | 0.780 | 0.764 | 0.177 | 0.0763 | 0.104 |